Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2008 2
2009 5
2010 3
2011 8
2012 10
2013 10
2014 11
2015 16
2016 9
2017 11
2018 4
2019 12
2020 12
2021 16
2022 7
2023 6
2024 20
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team. Kelley CF, et al. Among authors: agwu al. N Engl J Med. 2025 Apr 3;392(13):1261-1276. doi: 10.1056/NEJMoa2411858. Epub 2024 Nov 27. N Engl J Med. 2025. PMID: 39602624 Clinical Trial.
Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America.
Horberg M, Thompson M, Agwu A, Colasanti J, Haddad M, Jain M, McComsey G, Radix A, Rakhmanina N, Short WR, Singh T, Tookes H. Horberg M, et al. Among authors: agwu a. Clin Infect Dis. 2024 Oct 12:ciae479. doi: 10.1093/cid/ciae479. Online ahead of print. Clin Infect Dis. 2024. PMID: 39393187 Free article.
Uptake of PrEP for Youth…Progress not Perfection.
Griffith DC, Agwu AL. Griffith DC, et al. Among authors: agwu al. Pediatrics. 2023 Nov 1;152(5):e2023063238. doi: 10.1542/peds.2023-063238. Pediatrics. 2023. PMID: 37899726 No abstract available.
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Moore CB, Baltrusaitis K, Best BM, Moye JH, Townley E, Violari A, Heckman B, Buisson S, Van Solingen-Ristea RM, Capparelli EV, Marzinke MA, Lowenthal ED, Ward S, Krotje C, Milligan R, Agwu AL, Huang J, Cheung SYA, McCoig C, Yin DE, Roberts G, Crauwels H, Van Eygen V, Zabih S, Masheto G, Ounchanum P, Aurpibul L, Korutaro V, Gaur AH; IMPAACT 2017 Collaborators for the IMPAACT 2017 Team. Moore CB, et al. Among authors: agwu al. Lancet HIV. 2025 Mar;12(3):e191-e200. doi: 10.1016/S2352-3018(24)00344-8. Lancet HIV. 2025. PMID: 40049924 Clinical Trial.
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED, Chapman J, Ohrenschall R, Calabrese K, Baltrusaitis K, Heckman B, Yin DE, Agwu AL, Harrington C, Van Solingen-Ristea RM, McCoig CC, Adeyeye A, Kneebone J, Chounta V, Smith-Anderson C, Camacho-Gonzalez A, D'Angelo J, Bearden A, Crauwels H, Huang J, Buisson S, Milligan R, Ward S, Bolton-Moore C, Gaur AH; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Lowenthal ED, et al. Among authors: agwu al. Lancet HIV. 2024 Apr;11(4):e222-e232. doi: 10.1016/S2352-3018(23)00301-6. Lancet HIV. 2024. PMID: 38538161 Free PMC article. Clinical Trial.
COVID-19 Cliff Notes: A COVID-19 Multidisciplinary Care Compendium.
Williams KM, Wilson PT, Silva-Palacios F, Kebbe J, LaBeaud AD, Agudelo H, Sidonio RF, Stowell SR, Josephson CD, Tarini BA, Holter Chakrabarty JL, Agwu AL. Williams KM, et al. Among authors: agwu al. Transplant Cell Ther. 2021 Jun;27(6):474.e1-474.e3. doi: 10.1016/j.jtct.2021.02.036. Epub 2021 Mar 3. Transplant Cell Ther. 2021. PMID: 33686384 Free PMC article.
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Gaur AH, Capparelli EV, Calabrese K, Baltrusaitis K, Marzinke MA, McCoig C, Van Solingen-Ristea RM, Mathiba SR, Adeyeye A, Moye JH, Heckman B, Lowenthal ED, Ward S, Milligan R, Samson P, Best BM, Harrington CM, Ford SL, Huang J, Crauwels H, Vandermeulen K, Agwu AL, Smith-Anderson C, Camacho-Gonzalez A, Ounchanum P, Kneebone JL, Townley E, Bolton Moore C; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Gaur AH, et al. Among authors: agwu al. Lancet HIV. 2024 Apr;11(4):e211-e221. doi: 10.1016/S2352-3018(23)00300-4. Lancet HIV. 2024. PMID: 38538160 Free PMC article. Clinical Trial.
168 results